Ardelyx’s Tenapanor: FDA Panel To Weigh Treatment Effect Size In Context Of Approved Agents

 
• By Sue Sutter
Small size
FDA says the small change in serum phosphorous levels with tenapanor raises questions about the drug's clinical benefit. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers